A pharmaceutical firm’s OTC business unit was stagnating in the US and underperforming internationally, so they turned to Marakon. We designed granular resource allocation strategies to unlock profitable growth in US while turning around Mexico and China businesses. These changes drove double digit top line and >2x EBIT in target regions and ultimately resulted in the sale of the business unit at 100% premium to intrinsic value.
Chasing growth: The rise, proliferation, and stagnation of alcoholic RTDs
Has the alcoholic RTD market crested and what’s next? Following notable growth between 2018 – 2020, alcoholic Ready-to-Drink (RTD) beverage sales seemed to...